Synapse - Margaret Callahan

Search Within

Margaret Kathleen Callahan

Results (197)

Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone

Meeting Abstract

Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)

Meeting Abstract

Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)

Meeting Abstract

Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Appendiceal enlargement during immunotherapy treatment for melanoma

Journal Article

Bello, D. M.; Callahan, M. K.; Busam, K.; Ariyan, C. E.
Clinical Skin Cancer (2016)

Fulltext@MSK | Save

Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies

Meeting Abstract

Lipson, E.; Gopal, A.; Neelapu, S. S.; Armand, P.; Spurgeon, S.; Leonard, J. P.; Hodi, F. S.; Sanborn, R. E.; Melero, I.; Gajewski, T. F.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients

Meeting Abstract

Zappasodi, R.; Li, Y.; Qi, J.; Wong, P.; Sirard, C.; Postow, M.; Newman, W.; Koon, H.; Velcheti, V.; Callahan, M. K.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study

Meeting Abstract

Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma

Meeting Abstract

Martin-Algarra, S.; Haanen, J. B.; Horak, C.; Bhatia, S.; Ribas, A.; Hwu, W. J.; Slingluff, C. L.; Sharfman, W. H.; Callahan, M.; Hodi, F. S.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade

Meeting Abstract

Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Journal Article

Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; Morse, M.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save